Atreca, Inc.: Nasdaq/NYSE listing notice — Atreca (BCEL) receives Nasdaq deficiency notice for bid price below $1.00; has 180 days to regain compliance

Atreca, Inc.

On Sep 7, 2023, average closing price of Class A common stock fell below $1.00 for 30 consecutive days, violating Nasdaq Listing Rule 5450(a)(1).
Company has 180-day grace period until March 6, 2024, to close at $1.00 or higher for at least 10 consecutive business days.
If not compliant by March 6, 2024, may qualify for an additional 180-day period by meeting other listing standards and indicating intent to effect a reverse stock split.
No immediate effect on trading; stock continues to trade on Nasdaq under symbol BCEL.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.99

Atreca, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

September 8, 2023, Atreca, Inc. (the “ Company ”) received notice from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying it that on September 7, 2023, the average closing price of the Company’s Class A common stock, $0.0001 par value per share (the “ Class A Common Stock ”), over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “ Minimum Bid Requirement ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days to r

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-23-100775

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.